By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Endocrine therapy is the mainstay of the management of hormone receptor (HR) positive breast cancer. Until now, fulvestrant remained the only selective
By Dr. Dipesh Uprety Karmanos Cancer Institute Four cycles of cisplatin-based adjuvant chemotherapy after surgical resection have remained the standard of care for patients with early-stage resectable non-small cell lung cancer
More
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Combination chemoimmunotherapy with the chemo regimen R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) has long stood as the standard of care
More
By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Attainment of pathological complete response (pCR) of breast cancer is associated with improved long-term outcomes (event-free survival and overall survival) compared to
More
By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Endocrine therapy is the mainstay of the management of hormone receptor (HR) positive breast cancer. Until now, fulvestrant remained the only selective
More
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary refractory Large b-cell lymphoma who were candidates
More
By Dr. Radhika Kulkarni Henry Ford Cancer Institute On March 2nd, 2023, results of the Phase 2 trial, SWOG 1801, (NCT03698019) were published in the New England Journal of Medicine. This
More
By Dr. Dipesh Uprety Karmanos Cancer Institute While immunotherapy is being used religiously for non-oncogene-addicted advanced non-small cell lung cancer, the activity of immunotherapy in oncogene-addicted non-small cell lung cancer is
More
By Dr. Tarik Hadid Wayne State University Human papillomavirus (HPV) is a small DS-DNA virus, and humans are the only known hosts. There are around 200 subtypes of the virus that
More
By Dr. Inas Abuali Massachusetts General Hospital There is a paucity of available treatment options for patients with advanced papillary renal cancer (PRC), a disease characterized by aggressive features and a
More
By Dr. Richa Parikh Karmanos Cancer Institute & Dr. Harsh Parmar Hackensack Meridian Health A multicenter retrospective study, which was conducted at 11 academic centers across the United States, reported a
More